UNLABELLED: What's known on the subject? and What does the study add? Previous studies have reported better outcomes in cancer patients that enrolled in clinical trials, suggesting that trial participation in itself might be beneficial. We investigated the potential positive effect of clinical trial participation on survival outcomes of patients with metastatic castration-resistant prostate cancer who were treated withfirst-line docetaxel-containing chemotherapy. After accounting for potential baseline inequalities, participation in a clinical trial itself was associated with significantly longer overall survival in these patients. OBJECTIVE: • To study differences in baseline characteristics and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-linedocetaxel-containing chemotherapy on prospective clinical studies (trial participants) versus those receiving this therapy outside of a clinical study (non-participants). PATIENTS AND METHODS: • Records from 247 consecutive chemotherapy-naive patients who were treated withdocetaxel-containing chemotherapyfor mCRPC at a single high-volume centre from 1998 to 2010 were reviewed. • All patients received docetaxel either as clinical trial participants (n= 142; 11 separate studies) or as non-participants (n= 105). • Univariable and multivariable Cox regression models predicted overall survival after chemotherapy initiation. RESULTS: • There was no significant difference between trial participation and non-participation with respect to patient age, type of primary treatment, tumour grade or clinical stage. • Multivariable analyses showed a significantly lower risk of all-cause mortality (hazard ratio 0.567; P= 0.027) among trial participants vs non-participants. CONCLUSIONS: • Patients that were treated with docetaxel for mCRPC showed a significantly longer overall survival when enrolled in a clinical trial. • Improved survival in trial participants may reflect the better medical oversight typically seen in patients enrolled in trials, more regimented follow-up schedules, or a positive effect on caregivers' attitudes because of greater contact with medical services. • With the retrospective nature of this analysis and the small study population, prospective studies are needed to validate the present findings and to further investigate the relationship between clinical trial participation and outcomes.
RCT Entities:
UNLABELLED: What's known on the subject? and What does the study add? Previous studies have reported better outcomes in cancerpatients that enrolled in clinical trials, suggesting that trial participation in itself might be beneficial. We investigated the potential positive effect of clinical trial participation on survival outcomes of patients with metastatic castration-resistant prostate cancer who were treated with first-line docetaxel-containing chemotherapy. After accounting for potential baseline inequalities, participation in a clinical trial itself was associated with significantly longer overall survival in these patients. OBJECTIVE: • To study differences in baseline characteristics and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy on prospective clinical studies (trial participants) versus those receiving this therapy outside of a clinical study (non-participants). PATIENTS AND METHODS: • Records from 247 consecutive chemotherapy-naive patients who were treated with docetaxel-containing chemotherapy for mCRPC at a single high-volume centre from 1998 to 2010 were reviewed. • All patients received docetaxel either as clinical trial participants (n= 142; 11 separate studies) or as non-participants (n= 105). • Univariable and multivariable Cox regression models predicted overall survival after chemotherapy initiation. RESULTS: • There was no significant difference between trial participation and non-participation with respect to patient age, type of primary treatment, tumour grade or clinical stage. • Multivariable analyses showed a significantly lower risk of all-cause mortality (hazard ratio 0.567; P= 0.027) among trial participants vs non-participants. CONCLUSIONS: • Patients that were treated with docetaxel for mCRPC showed a significantly longer overall survival when enrolled in a clinical trial. • Improved survival in trial participants may reflect the better medical oversight typically seen in patients enrolled in trials, more regimented follow-up schedules, or a positive effect on caregivers' attitudes because of greater contact with medical services. • With the retrospective nature of this analysis and the small study population, prospective studies are needed to validate the present findings and to further investigate the relationship between clinical trial participation and outcomes.
Authors: M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245
Authors: William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: D M Savarese; S Halabi; V Hars; W L Akerley; M E Taplin; P A Godley; A Hussain; E J Small; N J Vogelzang Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell Journal: Br J Cancer Date: 2003-06-16 Impact factor: 7.640
Authors: U Andergassen; N S Kasprowicz; P Hepp; C Schindlbeck; N Harbeck; M Kiechle; H Sommer; M W Beckmann; K Friese; W Janni; B Rack; C Scholz Journal: Geburtshilfe Frauenheilkd Date: 2013-01 Impact factor: 2.915
Authors: Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: BJU Int Date: 2014-02-14 Impact factor: 5.588
Authors: Joeri A J Douma; Laurien M Buffart; Ramy Sedhom; Mariette Labots; Willemien C Menke-van der Houven van Oordt; Mikkjal Skardhamar; Anthony De Felice; Esther Lee; Divya Dharmaraj; Nilofer S Azad; Michael A Carducci; Henk M W Verheul Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639
Authors: Malvin Torsvik; Lise Tuset Gustad; Arne Mehl; Inger Lise Bangstad; Liv Jorun Vinje; Jan Kristian Damås; Erik Solligård Journal: Crit Care Date: 2016-08-05 Impact factor: 9.097
Authors: Daniel Keizman; Keren Rouvinov; Avishay Sella; Maya Gottfried; Natalie Maimon; Jenny J Kim; Mario A Eisenberger; Victoria Sinibaldi; Avivit Peer; Michael A Carducci; Wilmosh Mermershtain; Raya Leibowitz-Amit; Rony Weitzen; Raanan Berger Journal: Cancer Res Treat Date: 2015-03-05 Impact factor: 4.679
Authors: Kyo Chul Koo; Jong Soo Lee; Jong Won Kim; Kyung Suk Han; Kwang Suk Lee; Do Kyung Kim; Yoon Soo Ha; Koon Ho Rha; Sung Joon Hong; Byung Ha Chung Journal: BMC Cancer Date: 2018-04-26 Impact factor: 4.430
Authors: Julia Dieter; Friederike Dominick; Alexander Knurr; Janko Ahlbrandt; Frank Ückert Journal: Methods Inf Med Date: 2021-04-22 Impact factor: 2.176